

NEWS & VIEWS REFERENCES

From the Ed's desk

1. <https://www.jcu.edu.au/news/releases/2023/march/mindfulness-can-help-diabetes-sufferers>
2. <https://www.liebertpub.com/doi/abs/10.1089/jicm.2022.0586>

Endometriosis may increase the risk of gestational diabetes

1. Salmeri, N., Li Piani, L., Cavoretto, P.I. et al. Endometriosis increases the risk of gestational diabetes: a meta-analysis stratified by mode of conception, disease localization and severity. *Sci Rep* 13, 8099 (2023). <https://doi.org/10.1038/s41598-023-35236-y>
2. Bosdou JK, Anagnostis P, Goulis DG, Lainas GT, Tarlatzis BC, Grimbizis GF, et al. Risk of gestational diabetes mellitus in women achieving singleton pregnancy spontaneously or after ART: a systematic review and meta-analysis. *Human Reproduction Update* [Internet]. 2020 Jun 18 [cited 2021 Mar 21];26(4):514–44. Available from: <https://academic.oup.com/humupd/article/26/4/514/5841325>
3. Vanni VS, Villanacci R, Salmeri N, Papaleo E, Delprato D, Ottolina J, et al. Concomitant autoimmunity may be a predictor of more severe stages of endometriosis. *Scientific Reports*. 2021 Jul 28;11(1).

Exercise and T2D Prevention

1. Luo M, Yu C, Del Pozo Cruz B, et al. Accelerometer-measured intensity-specific physical activity, genetic risk and incident type 2 diabetes: a prospective cohort study. *British Journal of Sports Medicine* Published Online First: 05 June 2023. doi: 10.1136/bjsports-2022-106653
2. UK Biobank. UK Biobank [Internet]. [ukbiobank.ac.uk](https://www.ukbiobank.ac.uk/). UK Biobank; 2019. Available from: <https://www.ukbiobank.ac.uk/>
3. <https://www.hsph.harvard.edu/obesity-prevention-source/moderate-and-vigorous-physical-activity/>

Embryonic vitamin D deficiency programs haematopoietic stem cells to induce T2D

1. Oh J, Riek AE, Bauerle KT, Dusso A, McNERNEY KP, Barve RA, et al. Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes. *Nature Communications* [Internet]. 2023 Jun 13;14(1):3278. Available from: <https://www.nature.com/articles/s41467-023-38849-z>
2. Savastio S, Cadario F, Beux S, Giorgis A, Genoni G, Bagnati M, et al. Vitamin D and Type I Diabetes. *The Open Rheumatology Journal* [Internet]. 2018 Dec 27;12(1). Available from: <https://openrheumatologyjournal.com/VOLUME/12/PAGE/289/FULLTEXT/#r2>
3. Farahmand MA, Daneshzad E, Fung TT, Zahidi F, Mohammadi M, Bellissimo N, et al. What is the impact of vitamin D supplementation on glycemic control in people with type-2 diabetes: a systematic review and meta-analysis of randomized controlled trails. *BMC Endocrine Disorders*. 2023 Jan 16;23(1).
4. Vondra K, Hampl R. Vitamin D and new insights into pathophysiology of type 2 diabetes. *Horm Mol Biol Clin Investig*. 2021 Mar 1;42(2):203-208. doi: 10.1515/hmbci-2020-0055. PMID: 33655734.

First Cellular Therapy to Treat T1D

1. Administration USF and D. FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes [Internet]. www.prnewswire.com. [cited 2023 Jul 19]. Available from: <https://www.prnewswire.com/news-releases/fda-approves-first-cellular-therapy-to-treat-patients-with-type-1-diabetes-301866374.html>
2. McNamee A. Lantidra wins FDA approval as first-ever type 1 diabetes cell therapy [Internet]. *Pharmaceutical Technology*. 2023 [cited 2023 Jul 19]. Available from: <https://www.pharmaceutical-technology.com/news/lantidra-wins-fda-approval-as-first-ever-type-1-diabetes-cell-therapy/#:~:text=The%20therapy%20works%20by%20essentially>
3. <https://www.fda.gov/media/169920/download> (Package Insert for Lantidra)
4. New Type 1 Diabetes Treatment Eliminates Need for Insulin [Internet]. *Verywell Health*. [cited 2023 Jul 19]. Available from: <https://www.verywellhealth.com/fda-approves-lantidra-to-treat-type-1-diabetes-7559545#citation-3>

New plant-based pro-insulin offers hope for oral T1D therapy

1. Kumar V, Choudhry I, Namdev A, Mishra S, Soni S, Hurkat P, et al. Oral Insulin: Myth or Reality. *Current Diabetes Reviews*. 2018 Oct 10;14(6):497–508.
2. Daniell H, Singh R, Mangu V, Nair SK, Wakade G, Balashova N. Affordable oral proinsulin bioencapsulated in plant cells regulates blood sugar levels similar to natural insulin. *Biomaterials* [Internet]. 2023 Jul 1 [cited 2023 Jun 15];298:122142. Available from: <https://www.sciencedirect.com/science/article/pii/S0142961223001503?via%3DiHub>

FEATURE REFERENCES

p10-16 Beyond Type 1 & Type 2: The less familiar types of diabetes

1. Diabetes: Australian facts, All diabetes [Internet]. Australian Institute of Health and Welfare. 2023. Available from: <https://www.aihw.gov.au/reports/diabetes/diabetes/contents/how-common-is-diabetes/all-diabetes>
2. Organization WH. Classification of diabetes mellitus [Internet]. <https://apps.who.int/iris/handle/10665/325182>
3. Furlanos, S., Dotta, F., Greenbaum, C. J., Palmer, J. P., Rolandsson, O., Colman, P. G., & Harrison, L. C. (2005). Latent autoimmune diabetes in adults (LADA) should be less latent. *Diabetologia*, 48(11), 2206–2212. <https://doi.org/10.1007/s00125-005-1960-7>
4. Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017). Adult-onset autoimmune diabetes: current knowledge and implications for management. *Nature reviews. Endocrinology*, 13(11), 674–686. <https://doi.org/10.1038/nrendo.2017.99>
5. Leslie, R. D., Palmer, J., Schloot, N. C., & Lernmark, A. (2016). Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. *Diabetologia*, 59(1), 13–20. <https://doi.org/10.1007/s00125-015-3789-z>
6. Davis, T. M., Wright, A. D., Mehta, Z. M., Cull, C. A., Stratton, I. M., Bottazzo, G. F., Bosi, E., Mackay, I. R., & Holman, R. R. (2005). Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). *Diabetologia*, 48(4), 695–702. <https://doi.org/10.1007/s00125-005-1690-x>
7. Davis, W. A., Peters, K. E., Makepeace, A., Griffiths, S., Bundell, C., Grant, S. F. A., Ellard, S., Hattersley, A. T., Paul Chubb, S. A., Bruce, D. G., & Davis, T. M. E. (2018). Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II. *Internal medicine journal*, 48(7), 803–809. <https://doi.org/10.1111/imj.13792>
8. Furlanos, S., Perry, C., Stein, M. S., Stankovich, J., Harrison, L. C., & Colman, P. G. (2006). A clinical screening tool identifies autoimmune diabetes in adults. *Diabetes care*, 29(5), 970–975. <https://doi.org/10.2337/diacare.295970>
9. Turner, R., Stratton, I., Horton, V., Manley, S., Zimmet, P., Mackay, I. R., Shattock, M., Bottazzo, G. F., & Holman, R. (1997). UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. *Lancet* (London, England), 350(9087), 1288–1293. [https://doi.org/10.1016/s0140-6736\(97\)03062-6](https://doi.org/10.1016/s0140-6736(97)03062-6)
10. Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020). Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. *Diabetes*, 69(10), 2037–2047. <https://doi.org/10.2337/dbi20-0017>
11. Brophy, S., Brunt, H., Davies, H., Mannan, S., & Williams, R. (2007). Interventions for latent autoimmune diabetes (LADA) in adults. *The Cochrane database of systematic reviews*, (3), CD006165. <https://doi.org/10.1002/14651858.CD006165.pub2>
12. Gudipaty, Lalitha. Rickels, Michael R. (2015). Pancreatogenic (Type 3c) Diabetes. *Pancreapedia: Exocrine Pancreas Knowledge Base*, DOI: 10.3998/panc.2015.35
13. Trang, T., Chan, J., & Graham, D. Y. (2014). Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century. *World journal of gastroenterology*, 20(33), 11467–11485. <https://doi.org/10.3748/wjg.v20.i33.11467>
14. Hart, P. A., Bellin, M. D., Andersen, D. K., Bradley, D., Cruz-Monserrate, Z., Forsmark, C. E., Goodarzi, M. O., Habtezion, A., Korc, M., Kudva, Y. C., Pandol, S. J., Yadav, D., Chari, S. T., & Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer(CPDPC) (2016). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. *The Lancet. Gastroenterology & hepatology*, 1(3), 226–237. [https://doi.org/10.1016/S2468-1253\(16\)30106-6](https://doi.org/10.1016/S2468-1253(16)30106-6)

p10-16 Beyond Type 1 & Type 2: The less familiar types of diabetes – Cont'd

15. Tang, H., Dong, X., Hassan, M., Abbruzzese, J. L., & Li, D. (2011). Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. *Cancer epidemiology, biomarkers & prevention*, 20(5), 779–792. <https://doi.org/10.1158/1055-9965.EPI-10-0845>
16. Wang, F., Herrington, M., Larsson, J., & Permert, J. (2003). The relationship between diabetes and pancreatic cancer. *Molecular cancer*, 2, 4. <https://doi.org/10.1186/1476-4598-2-4>
17. Hwangbo, Y., & Lee, E. K. (2017). Acute Hyperglycemia Associated with Anti-Cancer Medication. *Endocrinology and metabolism (Seoul, Korea)*, 32(1), 23–29. <https://doi.org/10.3803/EnM.2017.32.1.23>
18. Luna, B., & Feinglos, M. N. (2001). Drug-induced hyperglycemia. *JAMA*, 286(16), 1945–1948. <https://doi.org/10.1001/jama.286.16.1945>
19. Li, J. X., & Cummins, C. L. (2022). Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. *Nature reviews. Endocrinology*, 18(9), 540–557. <https://doi.org/10.1038/s41574-022-00683-6>
20. Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018). Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. *JAMA oncology*, 4(2), 173–182. <https://doi.org/10.1001/jamaoncol.2017.3064>
21. Wu, L., Tsang, V. H. M., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R., & Gunton, J. E. (2021). Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. *Frontiers in endocrinology*, 12, 764138. <https://doi.org/10.3389/fendo.2021.764138>
22. Zhan, L., Feng, H. F., Liu, H. Q., Guo, L. T., Chen, C., Yao, X. L., & Sun, S. R. (2021). Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. *Frontiers in endocrinology*, 12, 649863. <https://doi.org/10.3389/fendo.2021.649863>
23. Perdigoto, A. L., Quandt, Z., Anderson, M., & Herold, K. C. (2019). Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. *The Lancet. Diabetes & endocrinology*, 7(6), 421–423. [https://doi.org/10.1016/S2213-8587\(19\)30072-5](https://doi.org/10.1016/S2213-8587(19)30072-5)
24. Zhang H, Colclough K, Gloyn AL, Pollin TI. Monogenic diabetes: a gateway to precision medicine in diabetes. *Journal of Clinical Investigation*. 2021 Feb 1;131(3).
25. Sjöholm Å. Ketosis-Prone Type 2 Diabetes: A Case Series. *Frontiers in Endocrinology*. 2019 Oct 16;10.

p18-20 Living Guidelines: Medication for blood glucose management in adults with T2D

To view the full guidelines visit <https://www.diabetessociety.com.au/living-evidence-guidelines-in-diabetes/>

1. https://s3.amazonaws.com/files.magicapp.org/guideline/705211aa-4ad3-4d32-9f2c-2e71b0328696/files/NMA_results_with_placeholder_22_07_2020_amended_r268277.pdf

p22-25 Type 1 diabetes: Natural history and prevention

1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023;46(Suppl 1):S19-s40.
2. Diabetes data snapshots – NDSS [Internet]. www.ndss.com.au. Available from: <https://www.ndss.com.au/about-diabetes/diabetes-facts-and-figures/diabetes-data-snapshots/>
3. Australian Institute of Health and Welfare. Diabetes: Australian facts, Summary [Internet]. Australian Institute of Health and Welfare. 2022. Available from: <https://www.aihw.gov.au/reports/diabetes/diabetes/contents/summary>
4. International Diabetes Federation (IDF). IDF Diabetes Atlas 10th Edition (2021) Available at www.diabetesatlas.org Accessed 14 May 2023.
5. Haynes A, Bulsara MK, Bergman P, Cameron F, Couper J, Craig ME, et al. Incidence of type 1 diabetes in 0 to 14 year olds in Australia from 2002 to 2017. *Pediatr Diabetes*. 2020;21(5):707-12.
6. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. *Pediatric Diabetes*. 2018;19(3):346-53.
7. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. *Lancet*. 2016;387(10035):2340-8.
8. The Teddy Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. *Pediatric Diabetes*. 2007;8(5):286-98.
9. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children. *JAMA*. 2013;309(23):2473-9.
10. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care*. 2015;38(10):1964-74.

p22-25 Type 1 diabetes: Natural history and prevention – Cont'd

11. POInT study | GPPAD [Internet]. www.gppad.org. [cited 2023 Jun 5]. Available from: <https://www.gppad.org/en/point-study/>
12. Provention Bio, Inc. A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of PRV-101, a Coxsackie Virus B (CVB) Vaccine, in Healthy Adult Subjects [Internet]. clinicaltrials.gov. 2022 [cited 2023 Jun 5]. Available from: <https://clinicaltrials.gov/ct2/show/NCT04690426> (
13. Ziegler AG, Arnolds S, Kölln A, Achenbach P, Berner R, Bonifacio E, et al. Supplementation with *Bifidobacterium longum* subspecies *infantis* EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. *BMJ open* [Internet]. 2021 Nov 9 [cited 2023 Jun 5];11(11):e052449. Available from: <https://pubmed.ncbi.nlm.nih.gov/34753762/>
14. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. 2019;0(0):null.
15. Waibel M, Thomas HE, Wentworth JM, Couper JJ, MacIsaac RJ, Cameron FJ, et al. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial. *Trials*. 2022;23(1):433.
16. Medical University of Graz, Juvenile Diabetes Research Foundation. A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D) [Internet]. clinicaltrials.gov. 2022 [cited 2023 Jun 5]. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT04545151>
17. Wilhelm-Benartzi CS, Miller SE, Bruggaber S, et al Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. *BMJ Open* 2021;11:e053669. doi: 10.1136/bmjopen-2021-053669
18. Forlenza GP, McVean J, Beck RW, Bauza C, Bailey R, Buckingham B, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. *JAMA* [Internet]. 2023 Mar 28;329(12):990–9. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2801974>
19. Type1Screen – Screening for Type 1 Diabetes [Internet]. Available from: <https://type1screen.org/>
20. Type 1 Diabetes National Screening Pilot [Internet]. www.kidsdiabetesscreen.com.au. [cited 2023 Jun 5]. Available from: <https://www.kidsdiabetesscreen.com.au/>
21. ATIC [Internet]. atic.svi.edu.au. 2022 [cited 2023 Jun 5]. Available from: <https://atic.svi.edu.au/>

p26 – 29 PCOS & Diabetes: an overview of revised guidelines

1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. *Lancet*. 2007;370(9588):685-97.
2. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Human Reproduction*. 2010;25(2):544-51.
3. Gilbert E, Avery J, Bartlett R, Campbell S, Joham A, Rumbold A, et al. The Prevalence of Clinical Characteristics of Polycystic Ovary Syndrome among Indigenous Women: A Systematic Search and Review of the Literature. *Seminars in Reproductive Medicine*. 2021;39(3-4):78-93.
4. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. *The Journal of clinical endocrinology and metabolism*. 2017;102(2):604-12.
5. Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. *PLoS genetics*. 2018;14(12):e1007813.
6. Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. *Human reproduction (Oxford, England)*. 2017;32(12):2515-21.
7. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulinaemic clamp. *Human reproduction (Oxford, England)*. 2013;28(3):777-84.

p26 – 29 PCOS & Diabetes: an overview of revised guidelines – Cont'd

8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertility and sterility*. 2009;91(2):456-88.
9. Spritzer PM, Barone CR, Oliveira FB. Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management. *Curr Pharm Des*. 2016;22(36):5603-13.
10. Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies. *Human Reproduction*. 2016;31(11):2619-31.
11. Naderpoor N, Shorakae S, Joham A, Boyle J, De Courten B, Teede HJ. Obesity and polycystic ovary syndrome. *Minerva endocrinologica*. 2015;40(1):37-51.
12. Technical Report for the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Copyright Monash University, Melbourne, Australia, 2023 [
13. D'Arpe S, Di Felicianantonio M, Candelieri M, Franceschetti S, Piccioni MG, Bastianelli C. Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review. *Reprod Biomed Online*. 2016;33(4):436-48.
14. Bayona A, Martínez-Vaello V, Zamora J, Nattero-Chávez L, Luque-Ramírez M, Escobar-Morreale HF. Prevalence of PCOS and related hyperandrogenic traits in premenopausal women with type 1 diabetes: a systematic review and meta-analysis. *Hum Reprod Update*. 2022;28(4):501-17.
15. Long C, Feng H, Duan W, Chen X, Zhao Y, Lan Y, et al. Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: A systematic review and meta-analysis. *Frontiers in endocrinology*. 2022;13:980405.
16. Long C, Feng H, Duan W, Chen X, Zhao Y, Lan Y, et al. Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: A systematic review and meta-analysis. *Frontiers in endocrinology*. 2022;13.
17. Samaras K, McElduff A, Twigg SM, Proietto J, Prins JB, Welborn TA, et al. Insulin levels in insulin resistance: phantom of the metabolic opera? *The Medical journal of Australia*. 2006;185(3):159-61.
18. Haas DA, Carr BR, Attia GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. *Fertility and sterility*. 2003;79(3):469-81.
19. Fontes AFS, Reis FM, Cândido AL, Gomes KB, Tosatti JAG. Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. *European Journal of Clinical Pharmacology*. 2023;79(4):445-60.
20. Khattab R, Albannawi M, Alhajj Mohammed D, Alkubaish Z, Althani R, Altheeb L, et al. Metformin-Induced Vitamin B12 Deficiency among Type 2 Diabetes Mellitus' Patients: A Systematic Review. *Current Diabetes Reviews*. 2023;19(4):1-10.
21. Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, et al. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. *International journal of molecular sciences*. 2022;23(8).
22. Glendining KA, Campbell RE. Recent advances in emerging PCOS therapies. *Current Opinion in Pharmacology*. 2023;68.
23. Novo Nordisk Inc. D. Ozempic (semaglutide) Consumer Medicine Information 12/2017 [cited 06/06/2023]. [cited 06/06/2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf.
24. Hu L, Ma L, Xia X, Ying T, Zhou M, Zou S, et al. Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome. *The Journal of Clinical Endocrinology & Metabolism*. 2022;107(8):e3217-e29.
25. Benito E, Gómez-Martin JM, Vega-Piñero B, Priego P, Galindo J, Escobar-Morreale HF, et al. Fertility and Pregnancy Outcomes in Women with Polycystic Ovary Syndrome Following Bariatric Surgery. *The Journal of clinical endocrinology and metabolism*. 2020;105(9).
26. Butterworth J, Deguara J, Borg CM. Bariatric Surgery, Polycystic Ovary Syndrome, and Infertility. *Journal of obesity*. 2016;2016:1871594.
27. Monash Centre for Health Research and Implementation. AskPCOS <https://www.askpcos.org/> 2023 [Available from: <https://www.askpcos.org/>]

p32-34 Mediterranean diet & Type 2 diabetes

1. O'Hearn M, Lara-Castor L, Cudhea F, Miller V, Reedy J, Shi P, Zhang J, Wong JB, Economos CD, Micha R, Mozaffarian D; Global Dietary Database. Incident type 2 diabetes attributable to suboptimal diet in 184 countries. *Nat Med.* 2023 Apr;29(4):982-995. doi: 10.1038/s41591-023-02278-8. Epub 2023 Apr 17. PMID: 37069363; PMCID: PMC10115653.
2. Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. *BMC Med.* 2017 Jul 19;15(1):131. doi: 10.1186/s12916-017-0901-x. PMID: 28720102; PMCID: PMC5516328.
3. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). *Diabetes Care* 2018 Oct 4. doi:10.2337/180033.
4. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. *Diabetes Care* 2014 Jan;37(Suppl. 1):S120e43.
5. Sievenpiper JL, Dworatzek PD. Food and dietary pattern-based recommendations: an emerging approach to clinical practice guidelines for nutrition therapy in diabetes. *Can J Diabetes* 2013 Feb;37(1):51e7.
6. Nuha A, ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton, Deborah Young-Hyman, Robert A. Gabbay; on behalf of the American Diabetes Association, 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023. *Diabetes Care* 1 January 2023; 46 (Supplement_1): S68–S96. <https://doi.org/10.2337/dc23-S005>
7. The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: RACGP, 2020.
8. Papamichou D, Panagiotakos DB, Itsiopoulos C. Dietary patterns and management of type 2 diabetes: A systematic review of randomised clinical trials. *Nutr Metab Cardiovasc Dis.* 2019 Jun;29(6):531-543.
9. Mayr HL, Kostjasyn SP, Campbell KL, Palmer M, Hickman IJ. Investigating Whether the Mediterranean Dietary Pattern Is Integrated in Routine Dietetic Practice for Management of Chronic Conditions: A National Survey of Dietitians. *Nutrients.* 2020 Nov 4;12(11):E3395. doi: 10.3390/nu12113395. PMID: 33158299
10. Mayr HL, Kelly JT, Macdonald GA, et al. Clinician perspectives of barriers and enablers to implementing the Mediterranean dietary pattern in routine care for coronary heart disease and type 2 diabetes: a qualitative interview study. *Acad Nutr Diet* 2022; 122:1263–1282.
11. Milenkovic, T.; Bozhinovska, N.; Macut, D.; Bjekic-Macut, J.; Rahelic, D.; Velija Asimi, Z.; Burekovic, A. Mediterranean Diet and Type 2 Diabetes Mellitus: A Perpetual Inspiration for the ScientificWorld. A Review. *Nutrients* 2021, 13, 1307.)
12. Bach-Faig A, Berry EM, Lairon D, et al. Mediterranean diet pyramid today. Science and cultural updates. *Public Health Nutr.* 2011;14(12A):2274-84.
13. George ES, Kucianski T, Mayr HL, et al. A Mediterranean diet model in Australia: strategies for translating the traditional Mediterranean diet into a multicultural setting. *Nutrients.* 2018;10(4):465.
14. Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediterranean Diet; a Literature Review. *Nutrients.* 2015 Nov 5;7(11):9139-53.
15. Kouris-Blazos A, Itsiopoulos C (2014). Low all-cause mortality despite high cardiovascular risk in elderly Greek-born Australians: attenuating potential of diet? *Asia Pacific Journal of Clinical Nutrition* 23(4):532-544.
16. United Nations Educational SaCO. Intangible cultural heritage. Mediterranean diet. Accessed online <https://ich.unesco.org/en/RL/mediterranean-diet-00884#> 29 June 2022.
17. Murphy KJ, Parletta N. Implementing a Mediterranean-Style Diet Outside the Mediterranean Region. *Curr Atheroscler Rep.* 2018 May 4;20(6):28. doi:10.1007/s11883-018-0732-z.
18. Mayr HL, Tierney AC, Kucianski T, Thomas CJ, Itsiopoulos C. Australian patients with coronary heart disease achieve high adherence to 6-month Mediterranean diet intervention: preliminary results of the AUSMED Heart Trial. *Nutrition.* 2019 May;61:21-31. doi: 10.1016/j.nut.2018.10.027. Epub 2018 Nov 3. PMID: 30682704.

p32-34 Mediterranean diet & Type 2 diabetes – Cont'd

19. Itsiopoulos C, Brazionis L, Kaimakamis M, Cameron M, Best JD, O'Dea K, Rowley K. Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study. *Nutr Metab Cardiovasc Dis.* 2011 Sep;21(9):740-7.
20. Keyserling TC, Samuel-Hodge CD, Pitts SJ, Garcia BA, Johnston LF, Gizlice Z, Miller CL, Braxton DF, Evenson KR, Smith JC, Davis GB, Quenum EL, Elliott NT, Gross MD, Donahue KE, Halladay JR, Ammerman AS. A community-based lifestyle and weight loss intervention promoting a Mediterranean-style diet pattern evaluated in the stroke belt of North Carolina: the Heart Healthy Lenoir Project. *BMC Public Health.* 2016 Aug 5;16:732. doi: 10.1186/s12889-016-3370-9. PMID: 27495295; PMCID: PMC4975883.
21. Keys A, Mienotti A, Karvonen MJ, et al. The diet and 15-year death rate in the seven countries study. *Am J Epidemiol* 1986; 124:903–915.
22. Dinu M, Pagliai G, Casini A, et al. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. *Eur J Clin Nutr* 2018; 72:30–43.
23. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. *N. Engl. J. Med.* 2013, 368, 1279–1290.
24. Salas-Salvadó, J.; Bulló, M.; Babio, N.; Martínez-González, M.; Ibarrola-Jurado, N.; Basora, J.; Estruch, R.; Covas, M.I.; Corella, D.; Arós, F.; et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: Results of the predimed-reus nutrition intervention randomized trial. *Diabetes Care* 2010, 34, 14–19.
25. Vitale M, Masulli M, Calabrese I, Rivellesse AA, Bonora E, Signorini S, Perriello G, Squatrito S, Buzzetti R, Sartore G, Babini AC, Gregori G, Giordano C, Clemente G, Grioni S, Dolce P, Riccardi G, Vaccaro O; TOSCA.IT Study Group. Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 Diabetes: A Real-Life Study. *Nutrients.* 2018 Aug 10;10(8):1067. doi: 10.3390/nu10081067. PMID: 30103444; PMCID: PMC6115857.
26. Esposito K, Giugliano D. Mediterranean diet and type 2 diabetes. *Diabetes Metab Res Rev.* 2014 Mar;30 Suppl 1:34-40. doi: 10.1002/dmrr.2516. PMID: 24357346.
27. Esposito K, Maiorino MI, Ceriello A, Giugliano D. Prevention and control of type 2 diabetes by Mediterranean diet: a systematic review. *Diabetes Res Clin Pract.* 2010 Aug;89(2):97-102. doi: 10.1016/j.diabres.2010.04.019. Epub 2010 May 23. PMID: 20546959.
28. Esposito K, Maiorino MI, Bellastella G, Chiodini P, Panagiotakos D, Giugliano D. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. *BMJ Open.* 2015 Aug 10;5(8):e008222. doi: 10.1136/bmjopen-2015-008222. PMID: 26260349; PMCID: PMC4538272.
29. Itsiopoulos C, Mayr HL, Thomas CJ. The anti-inflammatory effects of a Mediterranean diet: a review. *Curr Opin Clin Nutr Metab Care.* 2022 Nov 1;25(6):415-422. doi: 10.1097/MCO.0000000000000872. Epub 2022 Aug 30. PMID: 36039924.
30. Xiong RG, Zhou DD, Wu SX, Huang SY, Saimaiti A, Yang ZJ, Shang A, Zhao CN, Gan RY, Li HB. Health Benefits and Side Effects of Short-Chain Fatty Acids. *Foods.* 2022 Sep 15;11(18):2863. doi: 10.3390/foods11182863. PMID: 36140990; PMCID: PMC9498509.
31. Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, et al. (2011) A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J Nutr* 141: 1140–1145.

-- ENDS --